Press Releases May 1, 2026 06:04 AM

AH Realty Trust Completes Sale of Construction Business, Advancing the Company’s Strategic Transformation and Focus on Long‑Term Shareholder Value

AH Realty Trust Finalizes Sale of Construction Business to Enhance Strategic Focus on Retail and Office Portfolio

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
AHRT

AH Realty Trust (NYSE: AHRT) completed the sale of its construction business for $2.4 million, marking a significant step in its strategic transformation. This move simplifies the company's business model and aligns with its objective to focus on operating a high-quality retail and office real estate portfolio, aiming for long-term shareholder value creation through operational excellence and a leaner operating model.

AH Realty Trust Completes Sale of Construction Business, Advancing the Company’s Strategic Transformation and Focus on Long‑Term Shareholder Value
AHRT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Completed sale of the construction business for $2.4 million, exiting non-core operations.
  • Focused shift towards managing a high-quality retail and office real estate portfolio primarily in the Mid-Atlantic and Southeastern US.
  • Strategic transformation aimed at operational excellence, predictable earnings, and sustainable cash-flow growth.

VIRGINIA BEACH, Va., May 01, 2026 (GLOBE NEWSWIRE) -- AH Realty Trust (NYSE: AHRT) (“AHRT”), formerly Armada Hoffler, today announced the completed sale of its construction business for a total consideration of $2.4 million.

The sale of AH Realty Trust’s construction business is another step in the Company’s transformation, further simplifying its business model and enhancing its prospects for long-term shareholder value creation. This transaction follows the recently announced sale of two multifamily notes from the Company’s real estate financing platform and supports the company’s objective to exit its non-core businesses and sharpen its focus on operating a high-quality retail and office portfolio.

“This transaction reflects the deliberate actions we are taking to simplify the Company and focus squarely on long‑term value creation,” said Shawn Tibbetts, Chairman, President and Chief Executive Officer of AH Realty Trust. “Exiting the construction business marks continued progress in our strategic transformation, as we reposition the organization around operational excellence and embrace a leaner, more agile operating model designed to deliver more predictable earnings and sustainable cash‑flow growth.”

About AH Realty Trust

AH Realty Trust (NYSE: AHRT), formerly known as Armada Hoffler, is a real estate investment trust (“REIT”) with over four decades of experience. The Company owns and operates high-quality retail and office assets located primarily in the Mid-Atlantic and Southeastern United States. AH Realty Trust focuses on disciplined capital allocation and long-term value creation for shareholders. For more information visit AHRealtyTrust.com.

Contact:
Chelsea Forrest
AH Realty Trust
EVP of Investor Relations and Administration
Email: chelsea.forrest@ahrealtytrust.com
Phone: (757) 366-4000


Risks

  • Potential challenges in achieving expected long-term value creation after divesting non-core businesses.
  • Market conditions affecting the retail and office real estate sectors, which the company now primarily operates in.
  • Possibility that the leaner and more agile operating model may face execution risks impacting earnings and cash flow.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026